Menu
We are glad to return to Swiss Biotech Day 2025, where you will have the chance to meet our BioPharma and Medical teams for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine.
Join us on May 5th at 16:45 pm, in the Montreal room, for an engaging panel discussion on the transformative role of AI-powered technology in building scalable, high-performance healthcare solutions. Discover how collaboration drives innovation and advances precision medicine.
Harnessing AI & Big Data: The Next Frontier in Biotech and Healthcare
Moderator:
Panelists:
We are thrilled to announce our presence at the 3rd edition of Artificial Intelligence for Oncology. You will have the chance to meet our BioPharma and Multimodal R&D experts and learn how we help BioPharma companies address challenges throughout the drug development continuum with data solutions tailored to their needs, bringing more effective drugs to the right patients.
If you are attending, don’t miss our talk on Friday, May 9th at 3.25pm, during the Industry Symposium.
“Accelerating Precision Oncology with Multimodal Data Analytics”
Hamza Boulaala, Data Scientist, Multimodal R&D, SOPHiA GENETICS
Join us in this session to learn how SOPHiA DDM™ for Multimodal is transforming the future of oncology, one breakthrough at a time:
We are excited to be at the 24th Annual Bio-IT World Conference & Expo. Join us at booth #724 and meet our BioPharma and Multimodal R&D experts to learn how we help BioPharma companies address challenges throughout the drug development continuum with data solutions tailored to their needs, bringing more effective drugs to the right patients.
If you are attending, don’t miss our talk on Friday, April 4th from 12.10 to 12.40pm, in the AI for Oncology, Precision Medicine & Health track.
“SOPHiA DDM™ for Multimodal: Advancing Precision Oncology with AI-Driven Analytics”
Paul Bernard, Data Engineer, Multimodal R&D, SOPHiA GENETICS
Join this session to explore how SOPHiA DDM™ for Multimodal is shaping the future of cancer care, one breakthrough at a time:
We are thrilled to be back at 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are around, don’t miss our plenary talk on Wednesday, April 9th from 11.30am to 12.00pm.
New and Innovative Ways to Democratize Precision Medicine Testing
Jess Lambe, Vice President and Managing Director of BioPharma Business Development, SOPHiA GENETICS
Join SOPHiA GENETICS at Pathology Update 2025 in Australia!
We are thrilled to announce our participation in the Pathology Update 2025, organized by the Royal College of Pathologists of Australasia (RCPA), for the very first time! This prestigious event will take place in Australia, showcasing the theme: 'Excellence in Diagnosis.'
Visit us at Booth #30 to discover how SOPHiA GENETICS is revolutionising the field of precision medicine. As clinicians and pathologists work tirelessly to achieve more accurate diagnoses and improve patient outcomes, we are here to support these efforts with our innovative, data-driven solutions.
Register to Pathology Update 2025 through here
SOPHiA GENETICS is thrilled to be back at ASCO 2025! Meet our experts at booth #32131 to hear about our biopharma solutions. Learn how we are leveraging our unique AI expertise, to provide an unparalleled offering, unlocking insights from complex data types, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines
SOPHiA GENETICS is thrilled to be back at AACR 2025! Visit us at booth #2856 to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions. By harnessing the power of AI and multimodal data-driven analytics, we enable you to advance and streamline global access to precision therapies.
Decentralized pan-cancer tumor profiling: A comprehensive performance evaluation of the MSK-IMPACT® Assay with SOPHiA DDM™
Presented by
Julien Pontis, PhD - Technical Product Manager and Lead Data Scientist, SOPHiA GENETICS
Fuad Mohammad, PhD - Senior Bioinformatican, Bioinformatics Product Development, SOPHiA GENETICS
Sunday, April 27 | 2 PM – 5 PM
Poster Board Number: 24
Real-World Insights into the Accuracy and Precision of the Decentralized MSK-ACCESS powered with SOPHiA DDM Solution
Presented by
Florian Klemm, MD, PhD - Technical Product Management Expert, Genomic Research , SOPHiA GENETICS
Monday, April 28 | 9 AM – 12 PM
Poster Board Number: 16
SOPHiA GENETICS is thrilled Charité Mayo Conference 2025! Visit us to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions.
We’re back at World Clinical Biomarkers & CDx Boston!
Join us to explore how you can harness the power of decentralization to drive global health equity.
With our universal, scalable and technology-agnostic platform now serving 750 customers across 72 countries, coupled with our expertise in developing and deploying decentralized genomic applications, we help you enhance patient and market access to relevant genomic information, and match patients to the right trials and treatments.
Development of an NGS-based ecDNA detection solution into a clinical trial device targeting oncogene amplification
September 5, 2024 | 03:10 to 03:40 PM | Track A
SPEAKERS
Julien Pontis, PhD
Technical Product Manager and Lead Scientist, SOPHiA GENETICS
Peter Krein, PhD
Vice President of Precision Medicine, Boundless Bio
David Lu, PhD
Director of Precision Medicine, Boundless Bio
It’s well established that patients with oncogene amplification generally do not benefit from standard-of-care cancer treatments and extrachromosomal DNA (ecDNA) has emerged as a unique biology of cancerous tumors.
Join us in this talk to hear about the Boundless Bio and SOPHiA GENETICS’s partnership on the development and validation of a prototype device for use in ecDNA-directed therapies.
Hear how the integration of ecDNA technology will impact the journey of patients with oncogene-amplified cancers.
Delve into the development and validation path to transform access to innovative precision therapies.
Learn about SOPHiA GENETICS’ unique ability to harmonize data derived from diverse genomic instruments and deploy as a robust, standardized solution enabling a decentralized model for clinical trial testing.
[et_pb_section admin_label="section"] [et_pb_row admin_label="row"] [et_pb_column type="4_4"][et_pb_text admin_label="Text"][/et_pb_text][/et_pb_column] [/et_pb_row] [/et_pb_section]SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.